Correction: Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials (Journal of the American Academy of Dermatology (2017) 76(3) (441–448.e2) (S0190962216310027) (10.1016/j.jaad.2016.10.027));Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials

Journal of the American Academy of Dermatology

Volumn 76, Issue 3, 2017, Pages 441-448.e2

  Reich, Kristian ^a   Leonardi, Craig ^b   Langley, Richard G ^c   Warren, Richard B ^d   Bachelez, Hervé ^e   Romiti, Ricardo ^f   Ohtsuki, Mamitaro ^g   Xu, Wen ^h   Acharya, Nayan ^h   Solotkin, Kathleen ^h   Colombel, Jean Frederic ⁱ   Hardin, Dana S ^h  

^a SCIderm Clinical Research and Dermatologikum   (Germany)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e Universite de Paris Diderot   (France)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

^g JICHI MEDICAL UNIVERSITY   (Japan)

^h ELI LILLY AND COMPANY   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

biologic therapy; Crohn's disease; inflammatory bowel disease; interleukin 17 antagonists; ixekizumab; psoriasis; ulcerative colitis

Indexed keywords

INTERLEUKIN 17; IXEKIZUMAB; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BIOLOGICAL THERAPY; CROHN DISEASE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); ULCERATIVE COLITIS; ADVERSE EFFECTS; CHEMICALLY INDUCED; COLITIS, ULCERATIVE; FACTUAL DATABASE; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; CROHN DISEASE; DATABASES, FACTUAL; DERMATOLOGIC AGENTS; FEMALE; HUMANS; INCIDENCE; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 85008178878     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2017.05.003     Document Type: Erratum

References (28)

1. 1 Skroza, N., Proietti, I., Pampena, R., et al. Correlations between psoriasis and inflammatory bowel diseases. Biomed Res Int, 2013, 2013, 983902.
2. 2 Ouyang, W., Kolls, J.K., Zheng, Y., The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28 (2008), 454–467.
3. 3 Cohen, A.D., Dreiher, J., Birkenfeld, S., Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol 23:5 (2009), 561–565.
4. 4 Egeberg, A., Mallbris, L., Warren, R.B., et al. Association between psoriasis and inflammatory bowel disease – a Danish nationwide cohort study. Br J Dermatol 175 (2016), 487–492.
5. 5 Christophers, E., Comorbidities in psoriasis. Clin Dermatol 25 (2007), 529–534.
6. 6 Strober, W., Fuss, I.J., Pro-inflammatory cytokines in the pathogenesis of inflammatory bowel disease. Gastroenterology 140 (2011), 1756–1767.
7. 7 Martin, D.A., Towne, J.E., Kricorian, G., et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol 133 (2013), 17–26.
8. 8 O'Connor, W. Jr., Kamanaka, M., Booth, C.J., et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 10 (2009), 603–609.
9. 9 Fujino, S., Andoh, A., Bamba, S., et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52 (2003), 65–70.
10. 10 Hueber, W., Sands, B.E., Lewitzky, S., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomized, double-blind placebo-controlled trial. Gut 61 (2012), 1693–1700.
11. 11 Targan, S.R., Feagan, B.G., Vermeire, S., et al. A randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe Crohn's disease. Am J Gastroenterol 111 (2016), 1599–1607.
12. 12 Gordon, K.B., Blauvelt, A., Papp, K.A., et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 375 (2016), 345–356.
13. 13 Griffiths, C.E., Reich, K., Lebwohl, M., et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomized trials. Lancet 386 (2015), 541–551.
14. 14 Gordon K, Blauvelt A, Langley R, et al. Ixekizumab for treatment of moderate-to-severe plaque psoriasis: 60-week results from a double-blind phase 3 induction and randomized withdrawal study (UNCOVER-1). Paper presented at: 73rd American Academy of Dermatology Annual Meeting. March 20-24, 2015; San Francisco, CA. Abstract F010.5.
15. 15 Krueger, J.G., Fretzin, S., Suárez-Fariñas, M., et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 130 (2012), 145–154.e9.
16. 16 Leonardi, C., Matheson, R., Zachariae, C., et al. Anti–interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366 (2012), 1190–1199.
17. 17 Callis Duffin, K., Bagel, J., Bukhalo, M., et al. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy, and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). J Eur Acad Dermatol Venereol 31 (2017), 107–113.
18. 18 Saeki, H., Nakagawa, H., Ishii, T., et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol 29 (2015), 1148–1155.
19. 19 Gower-Rousseau, C., Salomez, J.L., Dupas, J.L., et al. Incidence of inflammatory bowel disease in northern France (1988-1990). Gut 35 (1994), 1433–1438.
20. 20 Li, W.Q., Han, J.L., Chan, A.T., et al. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis 72 (2013), 1200–1205.
21. 21 Augustin, M., Reich, K., Glaeske, G., et al. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 90 (2010), 147–151.
22. 22 Lindberg, E., Tysk, C., Andersson, K., et al. Smoking and inflammatory bowel disease: a case control study. Gut 29 (1988), 352–357.
23. 23 Reif, S., Klein, I., Arber, N., et al. Lack of association between smoking and inflammatory bowel disease in Jewish patients in Israel. Gastroenterology 108 (1995), 1683–1687.
24. 24 Kennedy NA, Warner B, Johnston EL, et al. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. [Epub ahead of print Febuary 19, 2016]. Aliment Pharmacol Ther. http://dx.doi.org/10.1111/apt.13547.
25. 25 Torres, J., Boyapati, R.K., Kennedy, N.A., et al. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology 149 (2015), 1716–1730.
26. 26 Ye, Y., Pang, Z., Chen, W., et al. The epidemiology and risk factors of inflammatory bowel disease. Int J Clin Exp Med 8:12 (2015), 22529–22542.
27. 27 Teruel, C., Garrido, E., Mesonero, F., Diagnosis and management of functional symptoms in inflammatory bowel disease in remission. World J Gastrointest Pharmacol Ther 7 (2016), 78–90.
28. 28 Secukinumab [prescribing information], 2016, Novartis Pharmaceutical Corp, East Hanover, NJ.